Lilly’s Mounjaro Approved to Cut Heart-Risk in High-Risk Type 2 Diabetes

The FDA approved Eli Lilly’s diabetes drug Mounjaro (tirzepatide) to reduce the risk of heart attack or stroke in high‑risk adults with Type 2 diabetes, based on a trial showing an 8% lower rate of cardiovascular death, heart attack or stroke compared with Trulicity; Mounjaro is also marketed for weight loss as Zepbound. The piece highlights the growing GLP‑1 drug pipeline, including next‑generation therapies like retatrutide, and notes payer coverage trends that favor use for diabetes or cardiovascular risk reduction over obesity treatment.